Compare BIDU & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIDU | BDX |
|---|---|---|
| Founded | 2000 | 1897 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.1B | 51.5B |
| IPO Year | N/A | 1994 |
| Metric | BIDU | BDX |
|---|---|---|
| Price | $115.23 | $158.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $154.38 | ★ $188.73 |
| AVG Volume (30 Days) | 1.9M | ★ 2.2M |
| Earning Date | 02-26-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.69% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $7.54 | $2.22 |
| P/E Ratio | ★ $42.45 | $115.95 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $74.71 | $153.75 |
| 52 Week High | $165.30 | $230.95 |
| Indicator | BIDU | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 34.07 | 32.23 |
| Support Level | $108.01 | N/A |
| Resistance Level | $130.75 | $195.22 |
| Average True Range (ATR) | 3.33 | 3.51 |
| MACD | -0.19 | 0.31 |
| Stochastic Oscillator | 21.05 | 28.74 |
Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 70% of core revenue from online marketing services from its search engine in 2024. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.